欣母沛联合卡前列甲酯栓在乙肝孕妇瘢痕子宫二次剖宫产产后出血中的应用  

Application of Hemabate combined with Carboprost Methylate Suppositories in Second Cesarean Section Postpartum Hemorrhage of Hepatitis B Pregnant Women with Scar Uterus

作　　者：唐雍艳 张玉 张丽娜 TANG Yongyan;ZHANG Yu;ZHANG Li'na(Department of Obstetrics and Gynecology,Suzhou Fifth People's Hospital,Suzhou 215131,China)

机构地区：[1]苏州市第五人民医院妇产科,江苏苏州215131

出　　处：《临床医学工程》2022年第1期53-54,共2页Clinical Medicine & Engineering

摘　　要：目的 探讨欣母沛(卡前列素氨丁三醇)联合卡前列甲酯栓在乙肝孕妇瘢痕子宫二次剖宫产产后出血中的应用效果。方法 选择于我院行二次剖宫产的50例乙肝瘢痕子宫孕妇,随机分为观察组(欣母沛+卡前列甲酯栓)与对照组(卡前列甲酯栓)。比较两组的临床疗效、产后出血量、止血时间和不良反应。结果 观察组总有效率为96.00%,高于对照组的76.00%(P<0.05)。观察组产后2 h、 24 h出血量及止血时间少于对照组(P<0.05)。观察组的不良反应发生率为36.00%,与对照组的44.00%比较差异无统计学意义(P>0.05)。结论 欣母沛联合卡前列甲酯栓治疗乙肝孕妇瘢痕子宫二次剖宫产产后出血的效果较好,可减少出血量,缩短止血时间且安全性较高。Objective To explore the application effect of Hemabate(carboprost tromethamine)combined with carboprost methylate suppositories in second cesarean section postpartum hemorrhage of hepatitis B pregnant women.Methods 50 hepatitis B pregnant women with scar uterus undergoing second cesarean section were selected and randomly divided into observation group(Hemabate+carboprost methylate suppositories)and control group(carboprost methylate suppositories).The clinical efficacy,postpartum blood loss,hemostasis time and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 96.00%,higher than 76.00%of the control group(P<0.05).The postpartum 2-hour and 24-hour blood loss and hemostasis time of the observation group were less than those of the control group(P<0.05).The incidence of adverse reactions in the observation group was 36.00%,which had no statistical difference with 44.00%in the control group(P>0.05).Conclusions Hemabate combined with carboprost methylate suppositories in second cesarean section postpartum hemorrhage of hepatitis B pregnant women has better effect,which can reduce the blood loss,and shorten the hemostasis time,with higher safety.

关 键 词：欣母沛 卡前列甲酯栓 乙肝 孕妇 瘢痕子宫 二次剖宫产 产后出血 

分 类 号：R651.11[医药卫生—外科学]